RU2015148006A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2015148006A3 RU2015148006A3 RU2015148006A RU2015148006A RU2015148006A3 RU 2015148006 A3 RU2015148006 A3 RU 2015148006A3 RU 2015148006 A RU2015148006 A RU 2015148006A RU 2015148006 A RU2015148006 A RU 2015148006A RU 2015148006 A3 RU2015148006 A3 RU 2015148006A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361811464P | 2013-04-12 | 2013-04-12 | |
US61/811,464 | 2013-04-12 | ||
PCT/US2014/034021 WO2014169280A2 (en) | 2013-04-12 | 2014-04-14 | Deuterated nucleoside prodrugs useful for treating hcv |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015148006A RU2015148006A (ru) | 2017-05-18 |
RU2015148006A3 true RU2015148006A3 (ru) | 2018-08-01 |
Family
ID=50686233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015148010A RU2015148010A (ru) | 2013-04-12 | 2014-04-14 | Высокоактивное производное нуклеозида для лечения hcv |
RU2015148006A RU2015148006A (ru) | 2013-04-12 | 2014-04-14 | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015148010A RU2015148010A (ru) | 2013-04-12 | 2014-04-14 | Высокоактивное производное нуклеозида для лечения hcv |
Country Status (11)
Country | Link |
---|---|
US (2) | US9447132B2 (ru) |
EP (2) | EP2984097B1 (ru) |
JP (2) | JP2016518359A (ru) |
KR (2) | KR20160002896A (ru) |
CN (2) | CN105377868A (ru) |
AU (2) | AU2014250764A1 (ru) |
BR (2) | BR112015025766A2 (ru) |
CA (2) | CA2909270A1 (ru) |
ES (1) | ES2623287T3 (ru) |
RU (2) | RU2015148010A (ru) |
WO (2) | WO2014169280A2 (ru) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012003126A (es) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
PL2595980T3 (pl) | 2010-07-22 | 2015-03-31 | Gilead Sciences Inc | Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae |
CA2871547C (en) | 2012-05-25 | 2021-05-25 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
BR112016028119A2 (pt) | 2014-06-06 | 2017-08-22 | Res Triangle Inst | Agonistas receptores de apelina (apj) e usos dos mesmos |
HUE051986T2 (hu) | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
US20160016986A1 (en) * | 2014-07-21 | 2016-01-21 | Milind Deshpande | Stabilized nucleotides for medical treatment |
WO2016016447A1 (en) * | 2014-07-31 | 2016-02-04 | Sandoz Ag | Synthesis of phosphoramidates |
US10526363B2 (en) * | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN107108676A (zh) * | 2014-09-15 | 2017-08-29 | 美迪维尔公司 | 用于制备非对映异构纯的磷酰胺酯前药的方法 |
TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
WO2016073756A1 (en) * | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
US10683319B2 (en) | 2014-12-15 | 2020-06-16 | Emory University | Phosphoramidates for the treatment of hepatitis B virus |
WO2016098123A2 (en) * | 2014-12-16 | 2016-06-23 | Laurus Labs Private Ltd | A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers |
MA41441A (fr) * | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
EP3939985B1 (en) * | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
WO2016134053A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134058A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
CA2978085C (en) | 2015-03-06 | 2023-01-17 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
JP6743135B2 (ja) | 2015-09-02 | 2020-08-19 | アッヴィ・インコーポレイテッド | 抗ウィルス性テトラヒドロフラン誘導体 |
DK3349758T3 (da) | 2015-09-16 | 2022-06-13 | Gilead Sciences Inc | Fremgangsmåder til behandling af arenaviridae-virusinfektioner |
BR112018006206A2 (pt) * | 2015-09-29 | 2018-10-09 | Achillion Pharmaceuticals Inc | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa |
RU2766148C1 (ru) | 2015-12-09 | 2022-02-08 | Рисерч Трайэнгл Инститьют | Улучшенные агонисты апелинового рецептора (apj) и их использование |
CN106699828B (zh) * | 2016-01-04 | 2019-05-21 | 上海长森药业有限公司 | 氘代HCV NS5b抑制剂核苷酸衍生物及其用途 |
CA3029315A1 (en) * | 2016-06-24 | 2017-12-28 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
WO2018031818A2 (en) * | 2016-08-12 | 2018-02-15 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN107759632A (zh) * | 2016-08-19 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 一种手性磷酸酯的制备方法 |
CN116036114A (zh) | 2016-09-07 | 2023-05-02 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
US11292783B2 (en) | 2016-09-16 | 2022-04-05 | Research Triangle Institute | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists |
MX2019004214A (es) | 2016-10-12 | 2019-06-10 | Res Triangle Inst | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos. |
WO2018119076A1 (en) | 2016-12-21 | 2018-06-28 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
CN108276463A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一类新的化合物及其用途 |
JP7066728B2 (ja) | 2017-02-01 | 2022-05-13 | アテア ファーマシューティカルズ, インコーポレイテッド | C型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩 |
WO2018169946A1 (en) | 2017-03-14 | 2018-09-20 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
CN107987105B (zh) * | 2017-11-24 | 2019-10-01 | 无锡微色谱生物科技有限公司 | 一种可用于皮肤敷料的h2s给体化合物、海绵敷料和制备方法 |
KR102139340B1 (ko) | 2017-12-01 | 2020-07-29 | 주식회사 엘지생활건강 | 즉시 주름 개선 및 탄력 증진용 화장료 조성물 |
KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
CN110835358B (zh) * | 2018-08-16 | 2022-08-05 | 上海复星星泰医药科技有限公司 | 一种索磷布韦中间体的制备方法 |
CN110221064A (zh) * | 2019-05-23 | 2019-09-10 | 南京农业大学 | 猪塞尼卡谷病毒elisa抗体检测方法及应用 |
US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CN111233929B (zh) * | 2020-02-28 | 2023-02-28 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物的氘代物及其制备方法和用途 |
TW202309061A (zh) | 2020-03-12 | 2023-03-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
KR20230018473A (ko) | 2020-05-29 | 2023-02-07 | 길리애드 사이언시즈, 인코포레이티드 | 렘데시비르 치료 방법 |
MX2022016405A (es) | 2020-06-24 | 2023-01-30 | Gilead Sciences Inc | Análogos de nucleósido de 1¿-ciano y usos de estos. |
LT4204421T (lt) | 2020-08-27 | 2024-06-25 | Gilead Sciences, Inc. | Virusinių infekcijų gydymui skirti junginiai ir būdai |
CN116217632A (zh) * | 2021-12-06 | 2023-06-06 | 广州谷森制药有限公司 | 一种氘代胞苷衍生物的制备方法 |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2024020127A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
US5449664A (en) | 1988-11-21 | 1995-09-12 | Syntex (U.S.A.) Inc. | Antiviral agents |
CA2143678A1 (en) | 1992-09-10 | 1994-03-17 | Kevin P. Anderson | Compositions and methods for treatment of hepatitis c virus-associated diseases |
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
AU691527B2 (en) | 1993-09-17 | 1998-05-21 | Gilead Sciences, Inc. | Nucleotide analogs |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
CZ120699A3 (cs) | 1996-10-16 | 1999-09-15 | Icn Pharmaceuticals, Inc. | Monocyklická L-nukleosidová analoga a jejich využití |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
ATE212661T1 (de) | 1998-01-23 | 2002-02-15 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
JP5230052B2 (ja) | 2000-05-26 | 2013-07-10 | イデニクス(ケイマン)リミテツド | フラビウイルスおよびペスチウイルス治療のための方法および組成物 |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
KR20040028657A (ko) | 2000-10-18 | 2004-04-03 | 파마셋, 리미티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
KR100828453B1 (ko) | 2001-01-22 | 2008-05-13 | 머크 앤드 캄파니 인코포레이티드 | Rna 의존성 rna 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체 |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
GB2392157B (en) | 2001-05-16 | 2005-12-21 | Micrologix Biotech Inc | Nucleic acid-based compounds and methods of use thereof |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
EP1480982A4 (en) | 2002-02-14 | 2007-08-01 | Pharmasset Inc | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |
BR0309581A (pt) | 2002-05-06 | 2005-03-29 | Genelabs Tech Inc | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c |
WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
CN103275159A (zh) | 2002-06-28 | 2013-09-04 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
WO2004002422A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
EP1545558A4 (en) | 2002-09-24 | 2010-02-17 | Koronis Pharmaceuticals Inc | 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES |
AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
CA2542776A1 (en) | 2003-10-27 | 2005-05-12 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
KR100570697B1 (ko) | 2004-09-24 | 2006-04-12 | 삼성에스디아이 주식회사 | 연료 전지 시스템 및 이에 사용되는 개질기 |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
EP1893192A4 (en) | 2005-06-08 | 2010-03-31 | Univ North Carolina | METHOD FOR ENABLING SURVIVAL OF NERVE CELLS BASED ON NON-PEPTIDIC AND PEPTIDIC BDNF NEUROTROPHINE MIMETICS |
JP2009504704A (ja) | 2005-08-15 | 2009-02-05 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ウイルス4′−置換プロヌクレオチドホスホルアミダート |
US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
WO2007095269A2 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
WO2008005542A2 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
PL2041156T3 (pl) | 2006-07-13 | 2014-05-30 | Achillion Pharmaceuticals Inc | Peptydy 4-amino-4-oksobutanoilowe jako inhibitory replikacji wirusowej |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
EP2097451A2 (en) | 2006-12-22 | 2009-09-09 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
MX2009008139A (es) | 2007-01-31 | 2009-08-12 | Alios Biopharma Inc | Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. |
US8324179B2 (en) | 2007-02-09 | 2012-12-04 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2009058800A2 (en) | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
US20090181921A1 (en) | 2007-12-21 | 2009-07-16 | Alios Biopharma Inc. | 2-5a analogs and their methods of use |
CA2722308C (en) | 2008-04-15 | 2024-02-27 | Rfs Pharma, Llc. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
KR20110065440A (ko) | 2008-07-02 | 2011-06-15 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 바이러스 감염의 치료를 위한 화합물 및 제약 조성물 |
WO2010017547A1 (en) | 2008-08-08 | 2010-02-11 | Scinopharm Taiwan Ldt. | Process for making 5-azacytosine nucleosides and their derivatives |
GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
US8163707B2 (en) | 2008-09-15 | 2012-04-24 | Enanta Pharmaceuticals, Inc. | 4′-allene-substituted nucleoside derivatives |
PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
CN102245598B (zh) | 2008-12-10 | 2014-01-29 | 艾其林医药公司 | 病毒复制抑制剂4-氨基-4-氧代丁酰基肽环状类似物 |
PL2364309T3 (pl) | 2008-12-10 | 2015-03-31 | Achillion Pharmaceuticals Inc | Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji |
AU2010203416C1 (en) | 2009-01-09 | 2013-07-25 | Inhibitex, Inc. | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
KR101774429B1 (ko) | 2009-02-06 | 2017-09-04 | 코크리스탈 파마, 아이엔씨. | 암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭 |
US20100240604A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
EA201190178A1 (ru) | 2009-03-20 | 2012-06-29 | Алиос Биофарма, Инк. | Замещённые нуклеозидные и нуклеотидные аналоги |
JO3027B1 (ar) | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US20130085133A1 (en) | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
JP6058528B2 (ja) | 2010-03-31 | 2017-01-11 | ギリアド ファーマセット エルエルシー | ヌクレオシドホスホルアミデート |
TWI515000B (zh) | 2010-04-01 | 2016-01-01 | 伊迪尼克製藥公司 | 用於治療病毒感染之化合物及醫藥組合物 |
CA2804375C (en) * | 2010-07-19 | 2018-08-21 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
ES2514670T3 (es) | 2010-08-04 | 2014-10-28 | Herbert Schott | Fármacos dobles de bisfosfonato dirigidos al hueso |
WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US8871737B2 (en) | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
AU2011305652B2 (en) | 2010-09-22 | 2016-10-20 | Janssen Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
AR083221A1 (es) | 2010-09-29 | 2013-02-06 | Univ Nac Quilmes | Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato |
ES2605433T3 (es) | 2010-11-10 | 2017-03-14 | Janssen Products, L.P. | Fosforamidatos de espironucleósido oxetánico uracílico |
JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
WO2012092484A2 (en) | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
CN103403014B (zh) | 2011-01-03 | 2016-07-06 | 河南美泰宝生物制药有限公司 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
US9085599B2 (en) | 2011-03-16 | 2015-07-21 | Enanta Pharmaceuticals, Inc. | 2′allene-substituted nucleoside derivatives |
CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2012142085A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
CA2830689A1 (en) | 2011-04-13 | 2012-10-18 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
CN103687866A (zh) | 2011-05-19 | 2014-03-26 | Rfs制药公司 | 用于治疗病毒性感染的嘌呤单磷酸酯前药 |
US8809313B2 (en) | 2011-05-27 | 2014-08-19 | Achillion Pharmaceuticals, Inc. | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections |
KR20140064765A (ko) | 2011-06-30 | 2014-05-28 | 스텔라 에이피에스 | Hcv 조합 치료 |
US9408863B2 (en) | 2011-07-13 | 2016-08-09 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
WO2013009735A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
US20140234253A1 (en) | 2011-08-24 | 2014-08-21 | Glaxosmithkline Llc | Combination Treatments For Hepatitis C |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
CN103781496A (zh) | 2011-09-16 | 2014-05-07 | 艾伯维公司 | 用于治疗hcv的方法 |
WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物 |
WO2013066991A1 (en) | 2011-10-31 | 2013-05-10 | Inhibitex, Inc. | Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease |
US20130244966A1 (en) | 2011-12-12 | 2013-09-19 | Catabasis Pharmaceuticals, Inc. | Fatty acid antiviral conjugates and their uses |
US20130172240A1 (en) | 2011-12-28 | 2013-07-04 | Abbvie Inc. | Methods for treating hcv |
CA2857339C (en) | 2011-12-29 | 2015-11-17 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
-
2014
- 2014-04-14 US US14/252,290 patent/US9447132B2/en not_active Expired - Fee Related
- 2014-04-14 JP JP2016507702A patent/JP2016518359A/ja not_active Ceased
- 2014-04-14 US US14/252,494 patent/US20140309164A1/en not_active Abandoned
- 2014-04-14 CA CA2909270A patent/CA2909270A1/en not_active Abandoned
- 2014-04-14 BR BR112015025766A patent/BR112015025766A2/pt not_active Application Discontinuation
- 2014-04-14 WO PCT/US2014/034021 patent/WO2014169280A2/en active Application Filing
- 2014-04-14 KR KR1020157032206A patent/KR20160002896A/ko not_active Application Discontinuation
- 2014-04-14 BR BR112015025716A patent/BR112015025716A2/pt not_active IP Right Cessation
- 2014-04-14 EP EP14722955.3A patent/EP2984097B1/en active Active
- 2014-04-14 KR KR1020157032200A patent/KR20160003700A/ko not_active Application Discontinuation
- 2014-04-14 WO PCT/US2014/034018 patent/WO2014169278A1/en active Application Filing
- 2014-04-14 CA CA2909273A patent/CA2909273A1/en not_active Abandoned
- 2014-04-14 AU AU2014250764A patent/AU2014250764A1/en not_active Abandoned
- 2014-04-14 RU RU2015148010A patent/RU2015148010A/ru not_active Application Discontinuation
- 2014-04-14 JP JP2016507703A patent/JP2016522172A/ja active Pending
- 2014-04-14 CN CN201480033503.7A patent/CN105377868A/zh active Pending
- 2014-04-14 EP EP14724944.5A patent/EP2984098A2/en not_active Withdrawn
- 2014-04-14 ES ES14722955.3T patent/ES2623287T3/es active Active
- 2014-04-14 CN CN201480033500.3A patent/CN105705511A/zh active Pending
- 2014-04-14 RU RU2015148006A patent/RU2015148006A/ru not_active Application Discontinuation
- 2014-04-14 AU AU2014250762A patent/AU2014250762A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20160002896A (ko) | 2016-01-08 |
RU2015148010A (ru) | 2017-05-15 |
CA2909273A1 (en) | 2014-10-16 |
RU2015148006A (ru) | 2017-05-18 |
JP2016522172A (ja) | 2016-07-28 |
KR20160003700A (ko) | 2016-01-11 |
CA2909270A1 (en) | 2014-10-16 |
US20140309189A1 (en) | 2014-10-16 |
WO2014169280A2 (en) | 2014-10-16 |
ES2623287T3 (es) | 2017-07-10 |
CN105705511A (zh) | 2016-06-22 |
EP2984098A2 (en) | 2016-02-17 |
US9447132B2 (en) | 2016-09-20 |
US20140309164A1 (en) | 2014-10-16 |
EP2984097A1 (en) | 2016-02-17 |
CN105377868A (zh) | 2016-03-02 |
AU2014250762A1 (en) | 2015-10-29 |
AU2014250764A1 (en) | 2015-10-29 |
WO2014169280A3 (en) | 2014-12-18 |
WO2014169278A1 (en) | 2014-10-16 |
RU2015148010A3 (ru) | 2018-04-28 |
JP2016518359A (ja) | 2016-06-23 |
BR112015025716A2 (pt) | 2017-07-18 |
EP2984097B1 (en) | 2017-03-29 |
BR112015025766A2 (pt) | 2017-10-17 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181115 |